Injective (INJ) shows bullish momentum at $3.41 with neutral RSI and key resistance breaks. Analysts target $3.50-$4.00 range within 4-6 weeks as technical indicatorsInjective (INJ) shows bullish momentum at $3.41 with neutral RSI and key resistance breaks. Analysts target $3.50-$4.00 range within 4-6 weeks as technical indicators

INJ Price Prediction: Targets $3.50-$4.00 by March Amid Technical Recovery Signals

2026/02/21 14:43
5 min read

INJ Price Prediction: Targets $3.50-$4.00 by March Amid Technical Recovery Signals

Caroline Bishop Feb 21, 2026 06:43

Injective (INJ) shows bullish momentum at $3.41 with neutral RSI and key resistance breaks. Analysts target $3.50-$4.00 range within 4-6 weeks as technical indicators align.

INJ Price Prediction: Targets $3.50-$4.00 by March Amid Technical Recovery Signals

Injective Protocol (INJ) is showing signs of technical recovery after recent consolidation, with the token currently trading at $3.41 following a 4.76% daily gain. As we analyze the current market structure and technical indicators, several key price levels emerge for the coming weeks.

INJ Price Prediction Summary

Short-term target (1 week): $3.41-$3.57
Medium-term forecast (1 month): $3.50-$4.00 range
Bullish breakout level: $3.57
Critical support: $3.07-$3.24

What Crypto Analysts Are Saying About Injective

Recent analyst predictions paint a cautiously optimistic picture for Injective's price trajectory. Peter Zhang noted on February 18, 2026: "Injective (INJ) trades at $3.11 with neutral RSI at 34.86. Technical analysis suggests potential recovery to $3.50-$4.00 range by March 2026, with key resistance at $3.22."

Felix Pinkston provided a more detailed Injective forecast on February 15, stating: "INJ Price Prediction Summary: Short-term target (1 week): $3.41; Medium-term forecast (1 month): $3.41-$3.90 range; Bullish breakout level: $3.41; Critical support: $3.08."

Additionally, Caroline Bishop observed on February 14: "Injective (INJ) shows mixed signals at $3.20 with neutral RSI and bearish momentum. Technical analysis suggests potential recovery to $3.50-$4.00 range within 4-6 weeks if key resistance breaks."

The consensus among these analysts points to a $3.50-$4.00 target range, with key resistance levels that need to be overcome for sustained upward momentum.

INJ Technical Analysis Breakdown

The current technical picture for Injective presents several compelling signals. With INJ trading at $3.41, the token sits above its 7-day SMA ($3.22) and 20-day SMA ($3.23), indicating short-term bullish momentum. However, the price remains significantly below the 50-day SMA ($4.19) and 200-day SMA ($8.18), suggesting longer-term bearish pressure still exists.

The RSI reading of 46.61 places INJ in neutral territory, neither overbought nor oversold, which provides room for movement in either direction. The MACD histogram at 0.0000 indicates a potential momentum shift, though the overall MACD remains bearish at -0.2354.

Bollinger Bands analysis shows INJ positioned at 0.72 within the bands, with the upper band at $3.62 serving as immediate resistance. The current position suggests the token has room to move toward the upper band before encountering significant selling pressure.

Key trading levels reveal immediate resistance at $3.57 and strong resistance at $3.72. On the downside, immediate support sits at $3.24, with strong support at $3.07. The daily ATR of $0.25 indicates moderate volatility, typical for INJ's current trading range.

Injective Price Targets: Bull vs Bear Case

Bullish Scenario

In the bullish case for this INJ price prediction, a break above the immediate resistance level of $3.57 could trigger a rally toward $3.72 and eventually the $4.00 target cited by multiple analysts. The path higher would require:

  • Sustained trading volume above the recent 24-hour average of $7.06 million
  • RSI moving into the 50-60 range, confirming bullish momentum
  • A decisive break above the Bollinger Band upper limit at $3.62

If these conditions align, the medium-term target of $3.50-$4.00 becomes highly achievable within the next 4-6 weeks, representing potential gains of 17-25% from current levels.

Bearish Scenario

The bearish scenario for Injective forecast involves a failure to hold the current support structure. Key risk factors include:

  • A break below the immediate support at $3.24, which could trigger selling toward $3.07
  • Continued pressure from the significant gap to the 50-day SMA at $4.19
  • Overall crypto market weakness that could impact altcoin performance

In this scenario, INJ could retest the $3.07 strong support level, representing a potential 10% decline from current prices. A break below this level could see further downside toward the $2.84 Bollinger Band lower limit.

Should You Buy INJ? Entry Strategy

Based on the current technical setup, potential entry strategies for INJ include:

Conservative Approach: Wait for a pullback to the $3.24 support level for a lower-risk entry, with a stop-loss below $3.07. This provides a favorable risk-reward ratio for the $3.50-$4.00 upside targets.

Aggressive Approach: Enter on any break above $3.57 with conviction, using the $3.24 level as a stop-loss. This strategy captures momentum but carries higher risk if the breakout fails.

Risk management remains crucial given INJ's position below longer-term moving averages. Position sizing should account for the potential 10-15% downside risk to key support levels.

Conclusion

This INJ price prediction suggests a cautiously optimistic outlook for Injective Protocol in the coming weeks. The convergence of analyst targets around $3.50-$4.00, combined with improving short-term technical indicators, supports a bullish bias for the March timeframe.

However, investors should remain aware that INJ still trades well below its longer-term moving averages, and broader crypto market conditions will significantly impact price action. The technical setup favors the bulls if key resistance levels can be overcome with volume.

Disclaimer: Cryptocurrency price predictions are inherently speculative and carry significant risk. This analysis is for educational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock
  • inj price analysis
  • inj price prediction
Market Opportunity
4 Logo
4 Price(4)
$0.009231
$0.009231$0.009231
+4.56%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
Spur Protocol Daily Quiz 21 February 2026: Claim Free Tokens and Boost Your Crypto Wallet

Spur Protocol Daily Quiz 21 February 2026: Claim Free Tokens and Boost Your Crypto Wallet

Spur Protocol Daily Quiz February 21 2026: Today’s Correct Answer and How to Earn Free In-App Tokens The Spur Protocol Daily Quiz for February 21, 2026, is
Share
Hokanews2026/02/21 17:10
Big U.S. banks cut prime rate to 7.25% after Fed’s interest rate cut

Big U.S. banks cut prime rate to 7.25% after Fed’s interest rate cut

The post Big U.S. banks cut prime rate to 7.25% after Fed’s interest rate cut appeared on BitcoinEthereumNews.com. Big U.S. banks have lowered their prime lending rate to 7.25%, down from 7.50%, after the Federal Reserve announced a 25 basis point rate cut on Wednesday, the first adjustment since December. The change directly affects consumer and business loans across the country. According to Reuters, JPMorgan Chase, Citigroup, Wells Fargo, and Bank of America all implemented the new rate immediately following the Fed’s announcement. The prime rate is what banks charge their most trusted borrowers, usually large companies. But it’s also the base for what everyone else pays; mortgages, small business loans, credit cards, and personal loans. With this cut, borrowing gets slightly cheaper across the board. Inflation still isn’t under control. It’s above the 2% goal, and the impact of President Donald Trump’s tariffs remains uncertain. Fed reacts to rising unemployment concerns Richard Flynn, managing director at Charles Schwab UK, said jobless claims are at their highest in almost four years, despite the Fed originally planning to keep rates unchanged through the summer. “Although the summer began with expectations of holding rates steady, the labor market has shown more signs of weakness than anticipated,” Flynn said. Hiring has slowed because of uncertainty around Trump’s trade policy. Companies are hesitating to add staff, which is why job growth has nearly stalled. As fewer people are hired, spending starts to shrink. And that’s when things start to unravel. That’s what the Fed is trying to get ahead of with this rate cut. The cut also helps banks directly. Lower rates mean more people may qualify for loans again. During the previous rate hikes, lending standards got tighter. Now, with cheaper credit, smaller businesses could get approved again. If well-funded businesses feel confident, they may hire again. That could eventually help the consumer side of the economy bounce back, but that’s…
Share
BitcoinEthereumNews2025/09/18 16:32